CASSS Sharing Science Solutions Bioconjugate Virtual Summit 2026

Description

+ Include:  videos + file sub vtt +  pdf, size:  GB

+ Target Audience: Pharmacologists, Immunologists, Oncologists, and Biochemical Engineers

+ Sample video: contact me for sample video

+ Information:

The CASSS Virtual Summit on Bioconjugates is a one-day virtual program scheduled for May 28, 2026. Themed “Tackling Bioconjugate Challenges,” the summit focuses on addressing critical hurdles faced by bioconjugate developers and manufacturers, particularly emphasizing impurity control strategies and comparability assessments. The curriculum is delivered through targeted speaker presentations and interactive panel discussions.

Learning Objectives

• Identify and mitigate comparability risks, such as detecting new low-level heavy-heavy chain variants in Antibody-Drug Conjugates (ADCs).

• Evaluate impurity qualification requirements specifically for drug-linkers and their related impurities used to generate ADCs.

• Develop and characterize manufacturing processes for antibody-oligonucleotide conjugates.

• Manage bioconjugate heterogeneity related to drug-linkers and formulate charge variant control strategies for late-stage ADCs.

• Design risk-based analytical comparability strategies for ADCs navigating late-phase development.

• Apply Chemistry, Manufacturing, and Controls (CMC) regulatory considerations for ADCs from a strict biologics perspective.

Target Audience

This summit is designed for industry, regulatory, and academic professionals involved in the development, manufacturing, and quality control of biopharmaceuticals, specifically focusing on bioconjugates and antibody-drug conjugates (ADCs).

Best for Pharmacologists, Immunologists, Oncologists, and Biochemical Engineers.

Topics

• Analytical Comparability Approach for an Antibody Drug Conjugate

• Charge Variant Control Strategy for Late-Stage Antibody Drug Conjugates

• CMC Regulatory Considerations for Antibody-Drug Conjugates (ADCs) – From the Biologics Perspective

• Comparability Risk Mitigation Identification of a New Low-Level Heavy-Heavy Chain Variant in an ADC

• Designing Risk-Based Analytical Comparability Strategic Considerations for Antibody Drug Conjugates in Late-Phase Development

• Development and Characterization of Antibody-Oligonucleotides Conjugate Manufacturing Processes

• Impurity Qualification Requirements for Drug-Linkers Related Impurities Used to Generate Antibody-Drug Conjugates

• Managing Bioconjugate Heterogeneity Related to Drug-Linkers

• Session I Panel Discussion and Summary Closing Remarks

• Session II Panel Discussion and Summary Concluding Remarks